|Last Price||Today's Change||52-Week Range||Trading Volume|
|49.67||-0.30 (-0.60%)||32.51 - 50.29||5.3 million|
Market data as of 4:02PM 12/04/13. Quotes are delayed by at least 15 min.
AbbVie Releases First of Six Phase III Results from Investigational All-Oral, Interferon-Free, 12-week Regimen, Showing 96 Percent SVR12 in Genotype 1 Hepatitis C Patients New to Therapy
11/18/2013 8:00 AM ET